Fundraising FoxMitokinin
New York, US · Founded 2017 · 3 known investors
Find your way into Mitokinin
Sign up to see every warm intro you have to Mitokinin
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mitokinin team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Targeting mitochondria for neurodegenerative disease therapies.
Founders & leadership
Mitokinin was founded in 2017 by Nicholas Hertz.
NH
Nicholas HertzFounder
DC
Doug CrawfordNamed on SEC filing
DD
Daniel de Roulet, Jr.Named on SEC filing
Board
JF
Johannes FruehaufBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$9.5M disclosed across 2 rounds · 2017–2018
▶$5MraisedNov 2018 · 3 investors · BiotechnologyRule 506(b)
▶$5MraisedNov 2018 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas CrawfordDirector
- Peter ParkerDirector
- Nicholas HertzDirector
- Daniel de Roulet, Jr.Executive Officer, Director
- Offering amount
- $6M
- Amount sold
- $5M
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.5MraisedSep 2017 · 5 investors · BiotechnologyRule 506(b)
▶$4.5MraisedSep 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Doug CrawfordDirector
- Nicholas HertzDirector
- Daniel de Roulet, Jr.Executive Officer, Director
- Johannes FruehaufDirector
- Offering amount
- $4.5M
- Amount sold
- $4.5M
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Mitokinin do?
- Targeting mitochondria for neurodegenerative disease therapies.
- Who founded Mitokinin?
- Mitokinin was founded by Nicholas Hertz in 2017.
- Who are Mitokinin's investors?
- Mitokinin's investors include Mission Bay Capital, Mission Biocapital, Pfizer Venture Investments.
- How much funding has Mitokinin raised?
- Mitokinin has disclosed $9.5M raised across 2 rounds.
- Where is Mitokinin headquartered?
- Mitokinin is headquartered in New York, US.